The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | Real-world results in the UK for ibrutinib at first relapsed for MCL
In the United Kingdom, ibrutinib is funded as standard of care at first relapse for mantle cell lymphoma (MCL). Simon Rule, MD, Plymouth University, Plymouth, UK, discusses a study that analyzed the clinical effectiveness and tolerability of ibrutinib at first relapse in a non-clinical trial real-world population. Results indicate that response rates and the proportion of patients stopping ibrutinib due to toxicity were similar to trial data. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
